SkinBioTherapeutics(GB:SBTX)
GBXÂ 4.75+0.25 (+5.56%)
GB:SBTX
SkinBioTherapeutics financials statements
GBXÂ 4.75
At close:+0.25 (+5.56%)
Want to see GB:SBTX full AI Analyst Report?
SkinBioTherapeutics (SBTX) Ratios
25 Followers
SkinBioTherapeutics Ratios
GB:SBTX's free cash flow for Q2 2025 was £-1.55M. For the 2025 fiscal year, GB:SBTX's free cash flow was decreased by £-21.58K and operating cash flow was £-1.53M. See a summary of the company’s cash flow.
| Ratios | Jun 24 | Jun 23 | Jun 22 | Jun 21 | Jun 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.84 | 0.93 | 3.25 | 4.58 | 12.50 |
| Quick Ratio | 4.29 | 0.66 | 3.19 | 4.34 | 12.50 |
| Cash Ratio | 3.25 | 0.44 | 2.48 | 3.55 | 11.39 |
| Solvency Ratio | -0.10 | -1.20 | -4.66 | -4.53 | -2.75 |
| Operating Cash Flow Ratio | -0.88 | -1.51 | -4.99 | -5.25 | -3.84 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -3.68 | -85.20 | 84.03 | -62.02 |
| Net Current Asset Value | £ 4.40M | £ -573.77K | £ 1.12M | £ 1.72M | £ 4.54M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.16 | 0.04 | 0.04 | 0.02 |
| Debt-to-Equity Ratio | 0.11 | 0.28 | 0.05 | 0.05 | 0.03 |
| Debt-to-Capital Ratio | 0.10 | 0.22 | 0.05 | 0.05 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.76 | 1.30 | 1.25 | 1.10 |
| Debt Service Coverage Ratio | -1.93 | -3.35 | -69.67 | 126.99 | -54.88 |
| Interest Coverage Ratio | -8.99 | -56.52 | -337.54 | -294.24 | -1613.77 |
| Debt to Market Cap | 0.02 | 0.04 | 0.00 | -0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 19.26 | -0.01 | 0.41 | 0.57 | 3.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 58.33% | 56.50% | 64.51% | 60.64% | 0.00% |
| EBIT Margin | -13.43% | -239.62% | -2271.26% | -3988.83% | 0.00% |
| EBITDA Margin | -4.24% | -225.14% | -2237.79% | -3949.14% | 0.00% |
| Operating Profit Margin | -17.83% | -240.28% | -2271.26% | -3988.83% | 0.00% |
| Pretax Profit Margin | -15.42% | -243.92% | -2277.98% | -4002.38% | 0.00% |
| Net Profit Margin | -15.01% | -237.88% | -2146.91% | -3735.37% | 0.00% |
| Continuous Operations Profit Margin | -15.01% | -237.88% | -2146.91% | -3735.37% | 0.00% |
| Net Income Per EBT | 97.36% | 97.52% | 94.25% | 93.33% | 95.66% |
| EBT Per EBIT | 86.49% | 101.51% | 100.30% | 100.34% | 100.25% |
| Return on Assets (ROA) | -5.74% | -55.15% | -109.29% | -90.52% | -24.99% |
| Return on Equity (ROE) | -7.39% | -96.84% | -142.12% | -112.82% | -27.48% |
| Return on Capital Employed (ROCE) | -7.76% | -85.18% | -145.28% | -115.76% | -28.04% |
| Return on Invested Capital (ROIC) | -7.48% | -67.63% | -132.92% | -108.23% | -26.57% |
| Return on Tangible Assets | -8.88% | -160.87% | -149.70% | -113.55% | -27.53% |
| Earnings Yield | -1.82% | -17.15% | -13.77% | -8.80% | -1.54% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.29 | 3.54 | 161.83 | 5.79 | 0.00 |
| Payables Turnover | 3.76 | 1.87 | 0.24 | 0.41 | 0.06 |
| Inventory Turnover | 2.42 | 1.11 | 1.40 | 0.24 | 0.00 |
| Fixed Asset Turnover | 6.37 | 10.39 | 0.76 | 0.59 | 0.00 |
| Asset Turnover | 0.38 | 0.23 | 0.05 | 0.02 | 0.00 |
| Working Capital Turnover Ratio | 1.68 | 2.29 | 0.09 | 0.02 | 0.00 |
| Cash Conversion Cycle | 165.23 | 235.87 | -1249.88 | 682.74 | -5692.84 |
| Days of Sales Outstanding | 111.06 | 103.00 | 2.26 | 62.99 | 0.00 |
| Days of Inventory Outstanding | 151.12 | 328.05 | 260.87 | 1520.47 | 0.00 |
| Days of Payables Outstanding | 96.95 | 195.17 | 1513.01 | 900.72 | 5692.84 |
| Operating Cycle | 262.18 | 431.04 | 263.13 | 1583.46 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 |
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -206.14 | -13.76 | -16.00 | -27.61 | -13.85 |
| Capital Expenditure Coverage Ratio | -206.14 | -13.76 | -16.00 | -27.61 | -13.85 |
| Operating Cash Flow Coverage Ratio | -1.31 | -3.33 | -26.28 | -20.91 | -11.12 |
| Operating Cash Flow to Sales Ratio | -0.28 | -2.26 | -20.03 | -35.75 | 0.00 |
| Free Cash Flow Yield | -3.41% | -17.44% | -13.65% | -8.72% | -1.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -54.19 | -5.83 | -7.26 | -11.37 | -65.01 |
| Price-to-Sales (P/S) Ratio | 8.25 | 13.87 | 155.91 | 424.66 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.06 | 5.65 | 10.32 | 12.83 | 17.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -29.35 | -5.73 | -7.33 | -11.46 | -55.87 |
| Price-to-Operating Cash Flow Ratio | -29.49 | -6.15 | -7.78 | -11.88 | -59.90 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | 0.56 | 2.15 | -0.14 | 4.00 |
| Enterprise Value Multiple | -175.51 | -6.17 | -6.56 | -10.19 | -59.44 |
| Enterprise Value | 34.50M | 16.78M | 19.38M | 30.07M | 88.68M |
| EV to EBITDA | -175.51 | -6.17 | -6.56 | -10.19 | -59.44 |
| EV to Sales | 7.44 | 13.88 | 146.74 | 402.23 | 0.00 |
| EV to Free Cash Flow | -26.45 | -5.74 | -6.90 | -10.86 | -53.19 |
| EV to Operating Cash Flow | -26.57 | -6.16 | -7.33 | -11.25 | -57.03 |
| Tangible Book Value Per Share | 0.02 | -0.00 | 0.01 | 0.01 | 0.03 |
| Shareholders’ Equity Per Share | 0.04 | 0.02 | 0.01 | 0.02 | 0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.02 | 0.06 | 0.07 | 0.04 |
| Revenue Per Share | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.02 | -0.02 | -0.02 | -0.01 |
| Tax Burden | 0.97 | 0.98 | 0.94 | 0.93 | 0.96 |
| Interest Burden | 1.15 | 1.02 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.03 | 0.47 | 7.05 | 11.52 | 0.00 |
| SG&A to Revenue | 0.08 | 0.06 | 0.28 | 0.38 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.70 | 0.00 |
| Income Quality | 1.82 | 0.92 | 0.93 | 0.96 | 1.09 |
Currency in GBP
